Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Total Current Liabilities (2019 - 2025)

Benitec Biopharma has reported Total Current Liabilities over the past 7 years, most recently at $2.8 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $2.8 million for Q4 2025, down 9.32% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (down 9.32% YoY), and the annual figure for FY2025 was $1.8 million, down 63.4%.
  • Total Current Liabilities reached $2.8 million in Q4 2025 per BNTC's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $7.0 million in Q1 2025 and bottomed at $1.4 million in Q2 2021.
  • Median Total Current Liabilities over the past 5 years was $2.9 million (2022), compared with a mean of $3.2 million.
  • The largest annual shift saw Total Current Liabilities soared 218.36% in 2021 before it crashed 63.4% in 2025.
  • Over 5 years, Total Current Liabilities stood at $2.5 million in 2021, then increased by 0.36% to $2.5 million in 2022, then surged by 130.86% to $5.7 million in 2023, then crashed by 46.24% to $3.1 million in 2024, then decreased by 9.32% to $2.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for BNTC at $2.8 million in Q4 2025, $2.0 million in Q3 2025, and $1.8 million in Q2 2025.